Dalriada Drug Discovery and Topos Bio Collaborate on IDP Drug Discovery Programs

• Dalriada Drug Discovery and Topos Bio have entered a collaboration to advance drug discovery targeting intrinsically disordered proteins (IDPs). 

• The partnership will leverage Dalriada’s chemoproteomics and mass spectrometry capabilities to support Topos Bio’s discovery programs. 

Dalriada Drug Discovery and Topos Bio have announced a collaboration to advance drug discovery efforts focused on intrinsically disordered proteins (IDPs), a class of targets that present challenges for conventional drug development approaches. 

Under the agreement, Topos Bio will use Dalriada’s expertise and infrastructure in protein mass spectrometry and chemoproteomics to support its discovery programs. The collaboration is intended to generate insights into protein structure and interactions that are typically difficult to characterize using traditional techniques. 

Intrinsically disordered proteins lack stable three-dimensional structures, making them difficult to target with standard drug discovery methods. The companies said the partnership aims to address these challenges by applying specialized analytical approaches to better understand protein behavior and identify potential therapeutic opportunities. 

Dalriada provides analytical and structural biology services to support drug discovery, while Topos Bio is focused on developing therapies targeting IDPs. The collaboration brings together complementary capabilities to support early-stage research and candidate identification. 

“We are excited to collaborate with Topos Bio to support their innovative approach to targeting intrinsically disordered proteins.” 

Chris Roberts, CEO of Dalriada Drug Discovery